Kim Jin-soo (biologist)

Kim Jin-Soo is a chemist, biologist, and entrepreneur. He was CEO and CSO, ToolGen, Inc., is a professor in the Department of Chemistry of Seoul National University and director of the Center for Genome Engineering. His research team has developed and improved several types of programmable nucleases, specifically zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs), and RNA-guided engineered nucleases (RGENs). In 2018, he was a Clarivate Analytics Highly Cited Researcher in the cross-field category and in the biology and biochemistry category in 2019.

Kim Jin-soo
Born(1964-05-29)May 29, 1964
Alma materSeoul National University, University of Wisconsin-Madison
AwardsHighly Cited Researcher (2018-2019), Asan Award in Medicine (2017)
Scientific career
FieldsZFN, TALEN, CRISPR/Cas9
InstitutionsHoward Hughes Medical Institute, Massachusetts Institute of Technology, Samsung Biomedical Research Institute, ToolGen, Seoul National University, Institute for Basic Science
Korean name
Hangul
Hanja
Revised RomanizationKim Jinsu
McCune–ReischauerKim Chinsu
WebsiteCenter for Genome Engineering

Education

Kim studied chemistry at Seoul National University from 1983 and received a B.S. in 1987 and M.S. in 1989. He received a Ph.D. from University of Wisconsin-Madison in 1994.

Career

He first worked as a research associate at the Howard Hughes Medical Institute and Massachusetts Institute of Technology for three years.[1] In 1997, he became a principal investigator at the Samsung Biomedical Research Institute.[2] In 1999, he left that position to be the CEO and CSO of ToolGen; a company he founded. ToolGen is a biotech company based on CRISPR technology focusing on human therapies, and molecular breeding in plants and animals.[3] In 2005, the company was among the Top 10 Biotech Companies to Watch in Asia at the Pacific Rim Forum/China Council for the Promotion of Industrial Trade.[4][1] In that same year, he left his CEO position and started working at Seoul National University as an assistant professor, then associate and then full professor. From 2014, he became the founding director of the Center for Genome Engineering under the Institute for Basic Science (IBS).[5]

CRISPR-Cas9 is a widely used genetic tool but testing its accuracy genome wide is difficult.[6] In 2015, Kim's IBS Center, Seoul National University, and ToolGen jointly published a paper in Nature Methods outlining their technique named Digenome-seq which locates on-target and off-target sequences in CRISPR-Cas9.[7] Dignome-seq complements other genome wide off target analysis assays such as CIRCLE-seq and guide-seq, which are performed in vitro and in cellulo, respectively. He has continued to research increasing the accuracy of the process.[8][9]

Awards and honors

See also

References
  1. "김진수 교수 약력". BRIC 한빛사 (in Korean). Retrieved 11 March 2020.
  2. "Director". Center for Genome Engineering. Seoul National University. Retrieved 12 March 2020.
  3. "About Us: Introduction". ToolGen Inc. Retrieved 12 March 2020.
  4. "(주)툴젠 김진수 박사". Biotech Information Portal (in Korean). 14 February 2005. Retrieved 11 March 2020.
  5. "Center for Genome Engineering". Institute for Basic Science. Retrieved 16 March 2020.
  6. "End of CRISPR-CAS9 controversy". Phys.org. 10 February 2015. Retrieved 16 March 2020.
  7. Kim, Daesik; Bae, Sangsu; Park, Jeongbin; Kim, Eunji; Kim, Seokjoong; Yu, Hye Ryeong; Hwang, Jinha; Kim, Jong-Il; Kim, Jin-Soo (9 February 2015). "Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells". Nature Methods. 12 (3): 237–243. doi:10.1038/nmeth.3284. PMID 25664545. S2CID 22626843. Retrieved 16 March 2020.
  8. Koo, Taeyoung; Lee, Jungjoon; Kim, Jin-Soo (30 June 2015). "Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9". Molecules and Cells. 38 (6): 475–481. doi:10.14348/molcells.2015.0103. PMC 4469905. PMID 25985872.
  9. 허, 지윤 (9 November 2017). "[헬스케어이노베이션 2017] 김진수 IBS 유전체교정연구단장 "빠르게 진화한 유전자가위 기술...정확도 높이는 연구가 중요"". Chosun Biz (in Korean). Retrieved 16 March 2020.
  10. "Seven IBS Scientists Named World's Most Highly Cited Researchers: Accounting for 13.1% of Korea's scientists on the list". Institute for Basic Science. 20 November 2019. Retrieved 6 March 2020.
  11. "IBS Places First Among Korean Institutions by Featuring 9 Scientists in List of Highly Cited Researchers". Institute for Basic Science. 4 December 2018. Retrieved 12 February 2019.
  12. "수상자 공적내용: 제10회 아산의학상 수상자 (2017년) - 기초의학부문 김진수 단장 (기초과학연구원 유전체교정연구단)". Asan Award in Medicine (in Korean). Asan Foundation. 2017. Retrieved 11 March 2020.
  13. "화학부 김진수 교수, 아산의학상 수상". SNU Now (in Korean). Seoul National University. Retrieved 11 March 2020.
  14. 장종원 (21 March 2017). "김진수 단장·한덕종 교수 '제10회 아산의학상' 수상". BioSpectator (in Korean). Retrieved 11 March 2020.
  15. 국가연구개발 우수성과 (PDF). Ministry of Science, ICT and Future Planning and Korea Institute of Science and Technology Evaluation and Planning (KISTEP). July 2014. p. 60.
  16. 김, 애경 (20 March 2014). "IBS 유전체교정연구단장에 김진수 서울대 교수". HelloDD (in Korean). Retrieved 11 March 2020.
  17. 최, 재근. "IBS 신규 연구단장에 서울대 김진수 교수 선정". 굿모닝충청 (in Korean). Retrieved 11 March 2020.
  18. "회원: 김진수 (金晋秀)". Korean Academy of Science and Technology (in Korean). Retrieved 11 March 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.